CO6612189A2 - Formulaciones orales sólidas y formas cristalinas de un inhibidor de la proteína de apoptosis - Google Patents

Formulaciones orales sólidas y formas cristalinas de un inhibidor de la proteína de apoptosis

Info

Publication number
CO6612189A2
CO6612189A2 CO12023091A CO12023091A CO6612189A2 CO 6612189 A2 CO6612189 A2 CO 6612189A2 CO 12023091 A CO12023091 A CO 12023091A CO 12023091 A CO12023091 A CO 12023091A CO 6612189 A2 CO6612189 A2 CO 6612189A2
Authority
CO
Colombia
Prior art keywords
solid oral
crystalline forms
oral formulations
protein inhibitor
apoptosis protein
Prior art date
Application number
CO12023091A
Other languages
English (en)
Spanish (es)
Inventor
Jeewan Thakur
Dong Yang
Lili Feng
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42937834&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6612189(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CO6612189A2 publication Critical patent/CO6612189A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
CO12023091A 2009-08-12 2012-02-09 Formulaciones orales sólidas y formas cristalinas de un inhibidor de la proteína de apoptosis CO6612189A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US27405109P 2009-08-12 2009-08-12

Publications (1)

Publication Number Publication Date
CO6612189A2 true CO6612189A2 (es) 2013-02-01

Family

ID=42937834

Family Applications (1)

Application Number Title Priority Date Filing Date
CO12023091A CO6612189A2 (es) 2009-08-12 2012-02-09 Formulaciones orales sólidas y formas cristalinas de un inhibidor de la proteína de apoptosis

Country Status (24)

Country Link
US (4) US8623385B2 (enExample)
EP (1) EP2464644A1 (enExample)
JP (3) JP2013501751A (enExample)
KR (2) KR20180020315A (enExample)
CN (2) CN102471331B (enExample)
AR (1) AR077869A1 (enExample)
AU (4) AU2010283748A1 (enExample)
BR (1) BR112012003118A2 (enExample)
CA (1) CA2769616A1 (enExample)
CL (1) CL2012000349A1 (enExample)
CO (1) CO6612189A2 (enExample)
IL (1) IL217760A0 (enExample)
IN (1) IN2012DN00858A (enExample)
MA (1) MA33511B1 (enExample)
MX (2) MX351274B (enExample)
MY (1) MY160475A (enExample)
PE (2) PE20170777A1 (enExample)
PH (1) PH12014501890B1 (enExample)
RU (1) RU2671196C1 (enExample)
SG (1) SG177713A1 (enExample)
TN (1) TN2012000026A1 (enExample)
TW (1) TWI607006B (enExample)
WO (1) WO2011018474A1 (enExample)
ZA (1) ZA201200390B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3020792A1 (en) 2016-04-20 2017-10-26 Glaxosmithkline Intellectual Property Development Limited Conjugates comprising ripk2 inhibitors
CN108484640B (zh) * 2018-05-22 2020-09-15 南京华威医药科技集团有限公司 一种抗肿瘤的细胞凋亡蛋白抑制剂
IL280880B2 (en) 2018-08-27 2025-04-01 Regeneron Pharma Using Raman Spectroscopy in Downstream Purification
HUP2200468A1 (hu) 2020-04-29 2023-03-28 X Chem Zrt IAP antagonisták és gyógyászati alkalmazásuk

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030124028A1 (en) * 2001-08-10 2003-07-03 Carlson Eric D. Apparatuses and methods for creating and testing pre-formulations and systems for same
US20060128632A1 (en) 2002-07-02 2006-06-15 Sharma Sushil K Peptide inhibitors of smac protein binding to inhibitor of apoptosis proteins (iap)
WO2005097791A1 (en) * 2004-04-07 2005-10-20 Novartis Ag Inhibitors of iap
EA019420B1 (ru) 2004-12-20 2014-03-31 Дженентех, Инк. Пирролидиновые ингибиторы иап (ингибиторов апоптоза)
PE20110224A1 (es) * 2006-08-02 2011-04-05 Novartis Ag PROCEDIMIENTO PARA LA SINTESIS DE UN PEPTIDOMIMETICO DE Smac INHIBIDOR DE IAP, Y COMPUESTOS INTERMEDIARIOS PARA LA SINTESIS DEL MISMO

Also Published As

Publication number Publication date
US20140093570A1 (en) 2014-04-03
AU2014213533A1 (en) 2014-09-04
KR20180020315A (ko) 2018-02-27
PE20170777A1 (es) 2017-07-04
AR077869A1 (es) 2011-09-28
CN102471331B (zh) 2016-01-13
US20180370960A1 (en) 2018-12-27
MX351274B (es) 2017-10-06
BR112012003118A2 (pt) 2016-02-23
MX2012001844A (es) 2012-02-29
AU2017254950B2 (en) 2018-09-20
IN2012DN00858A (enExample) 2015-07-10
CL2012000349A1 (es) 2012-09-07
WO2011018474A1 (en) 2011-02-17
IL217760A0 (en) 2012-03-29
SG177713A1 (en) 2012-02-28
PE20121132A1 (es) 2012-09-04
JP2013501751A (ja) 2013-01-17
PH12014501890A1 (en) 2015-09-14
RU2671196C1 (ru) 2018-10-30
TN2012000026A1 (en) 2013-09-19
US20170081319A1 (en) 2017-03-23
AU2016203145A1 (en) 2016-06-02
CN102471331A (zh) 2012-05-23
US20120128742A1 (en) 2012-05-24
MA33511B1 (fr) 2012-08-01
TW201118091A (en) 2011-06-01
KR20120048008A (ko) 2012-05-14
WO2011018474A8 (en) 2011-09-22
PH12014501890B1 (en) 2015-09-14
EP2464644A1 (en) 2012-06-20
JP2016179976A (ja) 2016-10-13
AU2017254950A1 (en) 2017-11-23
RU2012108931A (ru) 2013-09-27
US10093665B2 (en) 2018-10-09
CN105646471A (zh) 2016-06-08
JP2018172403A (ja) 2018-11-08
CA2769616A1 (en) 2011-02-17
US9540363B2 (en) 2017-01-10
ZA201200390B (en) 2012-10-31
AU2010283748A1 (en) 2012-02-09
MY160475A (en) 2017-03-15
US8623385B2 (en) 2014-01-07
TWI607006B (zh) 2017-12-01

Similar Documents

Publication Publication Date Title
ECSP12011659A (es) Formulaciones orales sólidas y formas cristalinas de un inhibidor de la proteína de apoptosis
DOP2012000150A (es) Triazolopiridinas
CL2012001911A1 (es) Compuestos derivados de fumarato; composicion farmaceutica que los comprende; y su uso en el tratamiento de una enfermedad inflamatoria o neurodegenerativa.
ECSP099775A (es) Terapia de combinación con un compuesto actuando como un inhibidor del receptor adp plaquetario
CU20110145A7 (es) Derivados de sulfonamida
DOP2014000133A (es) Triazolopiridinas sustituidas
DOP2013000244A (es) Triazolopiridinas
UY30500A1 (es) Compuestos de azabencimidazolilo
ECSP11011398A (es) Inhibidores de beta-secretasa
BRPI0721905B8 (pt) composto inibidor de proteassoma, sua composição farmacêutica e seu uso
UY33452A (es) Triazolopiridinas sustituidas
UY32153A (es) Inhibidores de piridomidinona de pi13ka(alfa) y mtor
GT200600346A (es) Nueva fórmula cristalina v de la agomelatina, un proceso para su preparación y composiciones farmacéuticas que la contienen
ECSP088700A (es) Acidos 4-fenil-tiazol-5-carboxilicos y amidas de acidos 4-fenil-tiazol-5-carboxilicos como inhibidores de la plk1
HN2006035237A (es) Derivados de triazolopiridina en calidad de inhibidores de lipasas y fosfolipasas
ECSP10010576A (es) Formulaciones orales e inyectables de compuestos de tetraciclina
CO6612189A2 (es) Formulaciones orales sólidas y formas cristalinas de un inhibidor de la proteína de apoptosis
ECSP10010597A (es) Nueva clase de espiro piperidinas para el tratamiento de enfermedades neurodegenerativas
MX2019009224A (es) Diacilhidrazina cristalina y sus usos.
AR051043A1 (es) Forma cristalina de clorhidrato de (3-cian-1h-indol-7il)-[4-(4-fluorofenetil)-piperazin-1-il]-metanona
AR077692A1 (es) Sales de 2-((r)-(3-clorofenil) ((r)-1-((s) -2-(metilamino)-3-((r)-tetrahidro-2h-piran-3-il) propilcarbamoil) piperidin -3-il) metoxi) etilcarbamato de metilo
ECSP11011053A (es) [4-(1-amino-etil)-ciclohexil]-metil-aminas como antibacterianos
CY1118132T1 (el) ΣΤΕΡΕΕΣ ΜΟΡΦΕΣ ΤΗΣ ΥΔΡΟΧΛΩΡΙΚΗΣ (1R,4R)-6'-ΦΘΟΡΟ-Ν,Ν-ΔΙΜΕΘΥΛ-4-ΦΑΙΝΥΛ-4',9'-ΔΙΥΔΡΟ-3´H-ΣΠΕΙΡΟ-[ΚΥΚΛΟΕΞΑΝΟ-1,1'-ΠΥΡΑΝΟ[3,4,b]ΙΝΔΟΛ]-4-ΑΜΙΝΗΣ
BRPI1010647A2 (pt) combinação de (a) um inibidor de fosfoinositídeo 3-quinase e (b) um composto antidiabético para uso no tratamento de doenças proliferativas
AR080203A1 (es) Formas solidas que comprenden una ciclopropilamida

Legal Events

Date Code Title Description
FC Application refused